Publication date: Available online 9 November 2018
Source: Journal of Allergy and Clinical Immunology
Author(s): Ayako Takamori, Kumi Izawa, Ayako Kaitani, Tomoaki Ando, Yoko Okamoto, Akie Maehara, Atsushi Tanabe, Masakazu Nagamine, Hiromichi Yamada, Shino Uchida, Koichiro Uchida, Masamichi Isobe, Tomoki Hatayama, Daiki Watanabe, Taiki Ando, Takuma Ide, Moe Matsuzawa, Keiko Maeda, Nobuhiro Nakano, Naoto Tamura
Ceramide-CD300f binding inhibits mouse Mrgprb2 (human MrgprX2)-mediated mast cell activation, thereby suppressing pseudo-allergic reactions. CD300f could be a therapeutic target against IgE-independent pseudo-allergy as well as IgE-dependent allergy.
from Allergy and Immunology via a.sfakia on Inoreader https://ift.tt/2DdjSuZ
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.